Wolverine Trading’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Wolverine Trading’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-32,900	Closed	-$3.32M	–	5297
2023 Q2	$3.32M	Buy	32,900 +22,300	+210%	+$2.11M	﹤0.01%	1160
2023 Q1	$954K	Buy	+10,600	New	+$622K	﹤0.01%	1934
2020 Q1	–	Sell	-7,500	Closed	-$1.53M	–	5505
2019 Q4	$1.53M	Buy	+7,500	New	+$1.37M	﹤0.01%	2041
2019 Q3	–	Sell	-4,500	Closed	-$425K	–	5213
2019 Q2	$425K	Buy	+4,500	New	+$389K	﹤0.01%	2887

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wolverine Trading's RETA Position: Q1 2020 in Review

Wolverine Trading sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2020, closing a stake of 8,485 shares — an estimated $1.74M sold.

Wolverine Trading first reported a position in RETA in Q1 2019 and held it in 4 quarters. The position peaked at $1.74M in Q4 2019. 214 funds tracked by Wall St. Rank hold RETA as of Q1 2020.

Wolverine Trading reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2020 after selling out during the quarter.
Wolverine Trading sold 8,485 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2020, an estimated $1.74M.
Wolverine Trading first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 4 quarters.
Wolverine Trading's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.74M in Q4 2019.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2020.

Based on Wolverine Trading's 13F filing for Q1 2020, filed 11 May 2020.